As in previous editions, the information has been obtained using a computer programme, and the print-out has not been type-set. The author points out the savings in cost, but the presentation is unattractive, and it is fortunate that the book is a reference source for specific items and need not be read as a whole.
This latest edition contains an additional 600 items, with a thorough coverage of the Japanese and Russian literature. There are both subject and author indices and the material is not restricted to specific chemicals but, for example, includes references to the effects of vaccines, viruses and dietary deficiencies. Inside the front and back covers there is also a useful The prospects of immunotherapy for clinical cancer have been kept bright for almost a century, not by the glow of gathering success but by the floodlight of promotion, iteration, promise and pretence that the seductive notion has inclined us to indulge. Now that the interim results of many hundreds of clinical trials are emerging, it is seen that the impressive vessel of ideas has, very largely, foundered in the cancer wards. To the disappointment of many clinical oncologists, who have acted on recommendations from laboratory-animal data of questionable clinical relevance, has been added a streak of indignation; even tumour immunologists are confessing to low spirits.
The fortunes of applied tumour immunology are evidently on a depression of their familiar undulation. Morale has to be restored, the image of novelty and excitement retouched, support retained, and a basis for rededication supplied. Professor Weiss here provides a strategy for redeployment.
The opening sentence of the text proclaims the dilemma: "The central hypothesis underlying all attempts at immunological intervention in neoplastic disease is today in danger of falling". The quotation from Nachman of Bratzlav which introduces the work ("It is forbidden to despair") betrays a mood which had been better not generated by precocious application of inflated theory.
In the last 20 years or so the scope for theoretical immunotherapy has been increasingly widened by striking advances in general immunology. The author, fitted by long experience and remarkable erudition in the field, by a facility for scrupulously phrased expression, and by a brilliance of optimistic imagination, has fashioned from these advances a phantasmagoria of possible clinical applications. The hazards and limitations of the more daring manoeuvres, such as the regional perfusion of allogeneic lymphocytes, grown up and sensitized to theoretical TSA (or TAA) in vitro, are frankly faced, only to be given a perhaps too confident promise of control. Enhancement, once treated as a hazard of immunotherapy, is recruited as an advantage to combined therapy: "neoplastic cells stimulated to proliferation can become more susceptible targets for concordant cytotoxic treatments".
Many visions familiar in the history of the topic are re-projected with a polish from the modern context and the author's style: cytotoxic agents being made to "home in" to a tumour on the backs of (now) monoclonal antibodies; the concept of cancer as a "neoplastic parasite"; prophylactic "vaccination" against some cancers; future discovery of oncogenic viruses in man; the bugbear of "escape" from "potential immune surveillance"; and the spectre of "idiosyncratic host immune failure".
If the intensity of optimism and the zeal of intellectual probing invite reservations and a kind of incredulity in the reader, he can be sure that Professor Weiss has anticipated every objection and pre-empted any ground for complaint. It is he who acknowledges that the matrix of his text is formed of "may", "could", "might", etc. But the disarming recital of conditionals and the mollifying play of doubt against confidence, of caution against boldness, should not be allowed to conceal some less explicit incongruities. Whilst admitting the impertinence of the unrealistic animal-model tumours which have been used to formulate clinical prescriptions, the author draws indiscriminately on information obtained from them, as given in many of the 460 references supporting his 62 pages of text.
What Professor Weiss intended he has done only too well; in the wake of widespread clinical disillusionment with theoretical tumour immunotherapy, he has reassured the committed that they can still be in businessbig business. But this may not be the best "psychological" moment to outline fresh projects; the crucial specific immunogen remains elusive! Soft-tissue tumours have been neglected by surgeons and pathologists. The outlook for patients with soft-tissue sarcoma has been bleak, with mutilating surgery the only available remedy, and all too often an unavailing one. The multiplicity of tumour types, together with the rarity of each type, has discouraged pathological endeavour in this field. There has been until now no available book on the pathology of soft-tissue tumours, while the advent of effective chemotherapy has emphasized the need for accurate diagnosis and agreed classification in this difficult area. Dr Hajdu's book, based on his great experience at the Memorial SloanKettering Cancer Center in New York, will therefore raise considerable expectations.
The book opens with an extended (and largely irrelevant) historical introduction, and there follow 9 chapters on the various soft-tissue tumours grouped by histogenesis. These provide a wealth of information, with excellent black and white photomicrographs, together with clinical photographs, radiographs, electron micrographs, etc. (The colour photomicrographs add nothing, except to the price of the book). Many pathologists will disagree with the very wide definition of the fibrous histiocytoma group, and all readers will be exasperated by the practice of arranging the references in chronological order. The presentation and cover design is somewhat gimmicky, and unworthy of a serious scientific work. But clinicians and pathologists concerned with this important group of tumours will certainly want to have this book available. The particular topic had last been covered in 1964, and I still refer to that volume when I can get hold of a copy. The new volume is also a glossy hard-backed book which has been published only a year after the Conference, without the benefit of cameraready manuscripts. Perhaps this explains the high cost, but the high quality of the review articles represents value for money which is not always found in conference proceedings.
There is something of value for most radiobiologists, starting with a keynote address on survival-curve models by Tikvah Alper and continuing with 12 articles on mechanisms of radiation injury including the Ernst W. Bertner Memorial Award lecture by Mortimer Elkind on Cells, Targets and Molecules in Radiation Biology.
A section on low doses and low dose rates includes papers in the field of radiation carcinogenesis. W. K. Russell concludes that "in nearly every example the tumorigenic effectiveness per rad of low-LET radiation tends to decrease with decreasing dose rate. For some tumor types the differences may be small or may appear only with very low dose rates, while for others the dose-rate effects may be large".
Tumour radiobiology is discussed both directlv in terms of the radiation response of a
